NCT00275613View on ClinicalTrials.gov

Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Glomerulonephritis, Membranoproliferative

Interventions

DRUG

Rituximab

The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Mayo Clinic

OTHER